– USA, MA – Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells for the treatment of cancer, today announced the appointment of Matthew Patterson, a biotechnology executive with nearly 30 years of experience in research, development, and commercialization of innovative treatments, to its Board of Directors.
“Matt is a highly respected leader in biotech, and for good reason,” said CEO, Robert Ang. “His expertise, guidance, and insights will be critical as we continue to advance our science towards the goal of developing potentially transformative therapies for patients with blood cancers.”
About Matt Patterson
Mr. Patterson has held senior leadership positions in both private and publicly-traded biotechnology companies. He is the co-founder of Audentes Therapeutics and was its CEO for eight years until its acquisition by Astellas Pharma in 2020; he also chaired the company’s Board of Directors and continues to serve as a strategic advisor to the company. Additionally, he is a member of the Board of Directors of Homology Medicines, Inc., and the Board of Directors of 5:01 Acquisition Corp. Mr. Patterson also currently serves as the Chairman of the Alliance for Regenerative Medicine, the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector.
Prior to Audentes, Mr. Patterson was an entrepreneur-in-residence with OrbiMed. Earlier in his career, he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics.
“Vor’s innovative approach to cell therapy and passionate team has the potential to transform the lives of cancer patients,” said Matt Patterson. “I am excited to provide guidance and mentorship to Robert and the team as they continue to build a world-class cell therapy company.”
Mr. Patterson received his bachelor’s degree in biochemistry from Bowdoin College.
About Vor Biopharma
Vor Biopharma aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell therapies. By removing biologically redundant proteins from eHSCs, these cells become inherently invulnerable to complementary targeted therapies while tumor cells are left susceptible, thereby unleashing the potential of targeted therapies to benefit cancer patients in need.
Vor’s platform could be used to potentially change the treatment paradigm of both hematopoietic stem cell transplants and targeted therapies, such as antibody-drug conjugates, bispecific antibodies, and CAR-T cell treatments.
Vor is based in Cambridge, Mass. and has a broad intellectual property base, including in-licenses from Columbia University, where foundational work was conducted by inventor and Vor Scientific Board Chair Siddhartha Mukherjee, MD, DPhil.
For more information: https://www.vorbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.